Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study
Authors:
- Björn HolmbergBHBjörn Holmberg
- Gregor WenningGWGregor Wenning
- Growth‐Hormone MSA Study GroupGGGrowth‐Hormone MSA Study Group
- 15 June 2007
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 22 (8) , 1138-1144
Abstract
The objective of this study was to investigate tolerability and possible neurotrophic effects of growth hormone (GH) in treatment of multiple system atrophy (MSA). In this double‐blind pilot study, MSA patients were randomized to recombinant human growth hormone (r‐hGH, n = 22), 1 mg every second day (6 months) followed by alternating daily injections of 1 mg and 0.5 mg (6 months), or matched placebo (n = 21). Safety analysis demonstrated no obvious between‐group differences. In both groups, there was progressive worsening of Unified Parkinson's Disease Rating Scale total score, which tended to be less in r‐hGH‐treated patients (12.9% at 6 months, 25.3% at 12 months) than in placebo (17.0% and 35.7%). Similarly, there was a trend to less worsening in Unified MSA Rating Scale total score with r‐hGH (13.2% and 21.2%) than with placebo (21.1% and 36.5%). Cardiovascular reflex autonomic testing also tended to show less deterioration with r‐hGH than with placebo at 12 months. However, 95% CI did not indicate treatment differences for any efficacy measures. In conclusion, r‐hGH administration in MSA patients for up to 1 year appears safe and might influence disease symptoms, signs and, possibly, progression. The results support further studies utilizing higher doses in more patients. © 2007 Movement Disorder SocietyKeywords
This publication has 22 references indexed in Scilit:
- Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation testAnnals of Neurology, 2006
- Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG)Movement Disorders, 2006
- The European Multiple System Atrophy-Study Group (EMSA-SG)Journal of Neural Transmission, 2005
- The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlationsBrain, 2004
- Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromesMovement Disorders, 2001
- Growth hormone and psychosocial and central nervous effects2000
- Multiple system atrophy: A review of 203 pathologically proven casesMovement Disorders, 1997
- Effects of Growth Hormone on Cerebral Development: Morphological StudiesHormone Research, 1996
- Correlation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiographyThe American Journal of Cardiology, 1988
- Decreased heart rate variability and its association with increased mortality after acute myocardial infarctionThe American Journal of Cardiology, 1987